With Astrid Spain
Addressing the issue of whether a biologically-active enantiomer of a patented drug is invalid over the prior art, the U.S. Court of Appeals for the Federal Circuit affirmed a district court decision that upheld the validity of Forest Laboratories’ U.S. Reissue Patent 34,712.